What's Happening?
Parexel, a global clinical development partner, is set to present two virtual research posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The research focuses on challenges in oncology drug development and the real-world
safety of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer. Additionally, Parexel is launching a new campaign, 'From Insights to Life,' which emphasizes the company's commitment to patient-centered clinical trials. This campaign aims to highlight the importance of patient experiences in clinical research, reinforcing Parexel's role as a leader in patient-first clinical development.
Why It's Important?
Parexel's initiatives at ASCO 2026 underscore the company's dedication to advancing oncology research and improving patient outcomes. By addressing common deficiencies in oncology marketing applications and focusing on real-world safety data, Parexel aims to enhance the development and approval process for new cancer therapies. The 'From Insights to Life' campaign further solidifies Parexel's commitment to integrating patient perspectives into clinical trials, which is crucial for developing treatments that truly meet patient needs. This approach not only benefits patients but also strengthens Parexel's position in the competitive clinical research industry.
What's Next?
Following the ASCO 2026 presentations, Parexel will continue to roll out its 'From Insights to Life' campaign throughout the year. The campaign will feature original compositions across digital and social channels, as well as activations at major biopharmaceutical industry events. Parexel's ongoing efforts to incorporate patient insights into clinical research are expected to influence future clinical trial designs and regulatory submissions, potentially leading to more patient-friendly and effective cancer treatments.
